![]() |
|||
Zerit (stavudine, d4T)January 2008 View PDF En
español What is Zerit? Zerit, manufactured by Bristol-Myers Squibb, was approved by the US Food and Drug Administration for the treatment of HIV in 1994. Three generic versions of stavudine have been approved for marketing in the United States. They were approved by the FDA in December 2008. Zerit must be used in combination with at least two other HIV drugs. What is known about Zerit? Children can also take Zerit. The dose for a child depends on their weight. If you are caring for a child who is HIV-positive and has been prescribed Zerit, be sure that you understand the correct dose to give the child. As a child grows, the dose of Zerit will need to be increased. Zerit can be taken either with or without food. Numerous studies have demonstrated that Zerit is effective for the treatment of HIV when combined with other HIV drugs, usually at least one other nucleoside reverse transcriptase inhibitor (NRTI) and either a protease inhibitor or non-nucleoside reverse transcriptase inhibitor (NNRTI). Zerit should not be taken alone (as monotherapy) or with just one other HIV drug. Because of its potential side effects, Zerit is no longer a recommended NRTI for HIV-positive adults beginning anti-HIV drug therapy for the first time, according to treatment guidelines issued by the United States Department of Health and Human Services. Tenofovir and emtricitabine, used together as Truvada or as a part of Atripla (efavirenz, tenofovir and emtricitabine), is listed as the "preferred" dual-NRTI option. The DHHS recommends against using Zerit and Videx EC (didanosine) together in the same drug combination. The risk of side effects, which are similar for Zerit and Videx EC, are increased when these drugs are used at the same time. Therapy with Zerit can cause certain changes (mutations) in HIV's structure to occur. Some mutations will prevent Zerit from working against HIV. Many of these mutations will also prevent Retrovir (zidovudine) from working against HIV. Some mutations can also prevent all of the NRTIs from working against HIV. If your viral load does not go undetectable or becomes detectable (and increases) while you are taking an HIV drug regimen that contains Zerit, your doctor can order a drug-resistance test to determine if your HIV has mutations that are causing resistance to Zerit and to help you figure out which NRTIs your HIV is still sensitive to. What about drug interactions? Zerit should not be combined with ribavirin (Rebetol; Copegus). Ribavirin is an oral medication used to treat hepatitis C. Ribavirin can affect the way Zerit is broken down by the body into its active form. This can make Zerit less effective against HIV. Methadone, a painkiller used to treat heroin addiction, can decrease Zerit levels in the bloodstream. Drug levels of methadone are not changed when combined with Zerit. There is no need to change the dose of either drug if they are used together. Combining Zerit with Videx EC, another NRTI, may increase the risk of developing lactic acidosis and other side effects. This is especially true in HIV-positive pregnant women who take both of these drugs together. In turn, the US Food and Drug Administration (FDA) has recommended that HIV-positive women not take these two drugs together while they are pregnant. The Department of Health and Human Services (DHHS) recommends that all HIV-infected adults and children avoid using these drugs together. Combining Zerit with Videx EC may increase the risk of developing peripheral neuropathy, a side effect caused by both drugs. The Department of Health and Human Services (DHHS) recommends that all HIV-infected adults and children avoid using these drugs together. What about side effects? Fatal and nonfatal pancreatitis (inflammation of the pancreas) has occurred with Zerit when taken in combination with Videx and other HIV drugs. Symptoms of pancreatitis include stomach pain, nausea, or vomiting. If you notice these symptoms, stop taking Zerit, and call your doctor right away. A common side effect of Zerit is peripheral neuropathy, which can result in pain, tingling, numbness, or burning in the hands and/or feet. Stopping Zerit and starting another nucleoside reverse transcriptase inhibitor (NRTI) that does not usually cause peripheral neuropathy — for example, Retrovir or Ziagen (abacavir) — is often the best way to stop peripheral neuropathy. Less common side effects include allergic reactions, loss of appetite, bone pain (arthralgia), stomach upset, headache, problems sleeping, muscle pain (myalgia), diarrhea, nausea, vomiting, anemia, and pancreatitis. These side effects improve within a few months/weeks of starting Zerit. There has been some concern that Zerit might cause, or at least contribute to, changes in body fat (lipodystrophy), most notably a loss of fat in the arms, legs, and face (lipoatrophy). A number of studies have demonstrated that Zerit is more likely to cause this problem than other NRTIs, particularly when it is used in combination with a protease inhibitor (protease inhibitors are also believed to cause changes in body fat). If you notice that the layer of fat beneath your skin in your arms, legs, or face appears to be becoming thinner — sunken cheeks and veiny arms and legs are common symptoms — you should discuss this with your doctor. If you and your doctor suspect that Zerit might be to blame, one option might be to stop therapy with Zerit and switch to another nucleoside reverse transcriptase inhibitor (NRTI). Can pregnant women take Zerit? It is not known whether Zerit passes into breast milk and what effects it may have on a nursing baby. However, to prevent HIV transmission of the virus to uninfected babies, it is recommended that HIV-positive mothers not breast-feed. Who should not take Zerit? Where can I learn more about clinical trials that are
using Zerit? If you would like to find out if you are eligible for any clinical trials that include Zerit, there is an interactive web site run by ACRIA, the AIDS Community Research Initiative of America. Another useful service for finding clinical trials is AIDSinfo.nih.gov, a site run by the US National Institutes of Health. They have "health information specialists" you can talk to at their toll-free number at 1-800-HIV-0440 (1-800-448-0440). |
OTHER LINKS |
||
|
© 2009 Project Inform 1375
Mission Street, San Francisco, CA 94103 415-558-8669 |
|||